Accolade (NASDAQ:ACCD) Announces Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Accolade (NASDAQ:ACCD) posted its earnings results on Thursday. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.13, Briefing.com reports. The company had revenue of $110.50 million for the quarter, compared to analysts’ expectations of $105.22 million. Accolade had a negative net margin of 24.09% and a negative return on equity of 22.53%. Accolade’s revenue for the quarter was up 18.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.52) earnings per share. Accolade updated its FY 2025 guidance to EPS and its Q2 2025 guidance to EPS.

Accolade Trading Down 44.0 %

NASDAQ:ACCD opened at $3.58 on Friday. Accolade has a 1 year low of $3.52 and a 1 year high of $15.36. The stock has a market cap of $286.44 million, a P/E ratio of -2.69 and a beta of 2.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.64. The stock has a 50-day simple moving average of $7.09 and a 200-day simple moving average of $9.66.

Insider Transactions at Accolade

In other Accolade news, CAO Colin Mchugh sold 5,543 shares of the stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $6.62, for a total value of $36,694.66. Following the transaction, the chief accounting officer now directly owns 50,177 shares in the company, valued at $332,171.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 14,746 shares of company stock valued at $104,586. Corporate insiders own 8.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $13.00 price objective on shares of Accolade in a research report on Monday, June 24th. Truist Financial cut their price objective on Accolade from $14.00 to $9.00 and set a “buy” rating on the stock in a report on Friday. Barclays lowered their target price on Accolade from $11.00 to $5.50 and set an “equal weight” rating for the company in a report on Friday. Guggenheim cut their price target on shares of Accolade from $13.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Stifel Nicolaus lowered their price objective on shares of Accolade from $13.00 to $8.00 and set a “buy” rating for the company in a research note on Friday. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Accolade presently has an average rating of “Moderate Buy” and a consensus price target of $11.89.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.